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Objectives This study sought to analyze stroke rates in the SYNTAX (Synergy Between Percutane-
ous Coronary Intervention With Taxus and Cardiac Surgery) trial’s randomized and registry cohorts
of patients being treated with coronary artery bypass grafting (CABG) or percutaneous coronary in-
tervention (PCI) for treatment of complex coronary artery disease.
Background The SYNTAX trial compared PCI to CABG in patients with de novo 3-vessel and/or left
main coronary disease.
Methods The SYNTAX randomized trial was conducted at 85 U.S. and European sites (n  1,800). All strokes
(up to 4 years) were independently adjudicated by a clinical events committee that included a neurologist. An
additional 1,077 (of which 644 were followed for 5 years) and 198 patients were included in the CABG and
PCI registries, respectively.
Results In the randomized cohort, 31 CABG and 19 PCI patients experienced 33 and 20 strokes post-ran-
domization at 4-year follow-up, respectively (p  0.062). Three strokes occurred pre-procedurally but following
andomization in CABG-treated patients. After CABG, a large proportion of strokes occurred acutely (0 to 30
ays: 9 of 33), whereas in the PCI arm, most strokes occurred 30 days after the procedure (18 of 20). Stroke
resulted in death in 3 patients in both the PCI and CABG groups. Of the patients who developed stroke, 68%
(21 of 31) in the CABG group had residual deﬁcits at discharge; in the PCI group, 47% (9 of 19) had residual
deﬁcits. In a multivariate analysis, treatment with CABG was not signiﬁcantly associated with increased stroke
rates (odds ratio: 1.67, 95% conﬁdence interval: 0.93 to 3.01, p  0.089). The incidence and outcomes of
stroke were similar in the randomized trial and registries.
Conclusions There is a higher risk of periprocedural stroke in patients undergoing CABG versus PCI;
however, the risk converges over the ﬁrst 4 years of follow-up. (SYNTAX Study: TAXUS Drug-Eluting
Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972) (J Am
Coll Cardiol Intv 2013;6:344–54) © 2013 by the American College of Cardiology Foundation
From the *Division of Cardiothoracic Surgery, Baylor Healthcare System, The Heart Hospital, Plano, Texas; †Departments of
Cardiothoracic Surgery and Cardiology, Erasmus University Medical Centre, Rotterdam, the Netherlands; ‡Department of
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345In the past few decades, differences in the rates of adverse
cardiac events, including death and myocardial infarction
after percutaneous coronary intervention (PCI) have
converged with coronary artery bypass grafting (CABG),
predominantly because PCI techniques and technology as
well as adjuvant medical therapy have improved (1–5).
Though CABG is the established method of revascular-
ization in patients with left main (LM) and 3-vessel
disease (3VD), PCI has become an increasingly used
alternative in this group of high-risk patients.
See page 355
Stroke, especially early post-operative stroke, is con-
sidered a serious risk for patients undergoing CABG but
not as much for patients receiving PCI (4 –7). The causes
of stroke following CABG are multifactorial and the
impact of newer surgical revascularization tech-
niques—no touch off-pump CABG— on the incidence of
stroke is uncertain. With the improved outcomes for PCI
using drug-eluting stents, the increase in the risk of
stroke with CABG needs to be weighed against the
increased likelihood of repeated revascularization.
Few randomized studies comparing CABG and PCI have
focused on stroke, and especially stroke during follow-up has
been an underrepresented analysis (8). The objective of
this post hoc analysis was to assess stroke in the large,
complex patient population enrolled in both the SYN-
TAX (Synergy Between Percutaneous Coronary Inter-
vention With Taxus and Cardiac Surgery) randomized
trial and nested registries and to define the risk factors
and outcomes of patients who experienced a stroke within
the first 4 years of follow-up.
Methods
Study design and treatment description. SYNTAX is a
rospective, multinational, randomized clinical trial (RCT)
N  1,800: CABG: n  897; PCI: n  903) with parallel
nested registries (CABG registry: n  1,077 of which n 
44 were followed for 5 years; PCI registry: n  198)
esigned to assess clinical outcomes after PCI with Taxus
University Hospital Uppsala, Uppsala, Sweden; Division of Cardiology, Evanston
Hospital, Evanston, Illinois; ¶Department of Cardiology, Ospedale San Raffaele, Milan,
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ompared with outcomes after CABG for the treatment of
e novo LM and/or 3VD. By consensus of the heart team,
onsisting of at least 1 interventional cardiologist and
ardiac surgeon, CABG-ineligible patients were enrolled in
PCI registry and PCI-ineligible patients were enrolled in
CABG registry (9,10). Trial design and detailed methods
f this study have been previously published (5,11). Analysis
f the subset of patients in the RCT with stroke was not
re-specified. Additionally, as the primary endpoint of
he overall SYNTAX study was not met (5), the results of
hese subgroup analyses are intended to be observational
nd hypothesis-generating and, therefore, should be in-
erpreted with caution.
The institutional review board at each participating site
pproved the study and all subjects provided written in-
ormed consent before enrollment. The protocol and con-
ent forms were consistent with
he International Conference on
armonisation Guidance for
ndustry E6 Good Clinical
ractice, the Declaration of Hel-
inki, and all local regulations, as
ppropriate. The study is registered
s identifier NCT00114972 on the
ational Institute of Heath’s
linicaltrials.gov website.
Deﬁnitions. A cerebrovascular
event, or stroke, was character-
ized by a focal neurological def-
icit lasting 72 h, resulting in
irreversible brain damage or per-
manent impairment. Confirma-
tion of neurological injury by head
computed tomography scan or
magnetic resonance imaging was
recommended. Strokes were also
classified as ischemic or hemorrhagic. In the randomized
controlled cohort of SYNTAX, all strokes were confirmed
by a local neurologist and adjudicated by an independent
clinical events committee (CEC) that included a neurolo-
gist. In the CABG and PCI registries, strokes were
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Abbreviations
and Acronyms
3VD  3-vessel disease
AF  atrial fibrillation
AFL  atrial flutter
CABG  coronary artery
bypass grafting
CEC  Clinical Events
Committee
CI  confidence interval
IQR  interquartile range
LM  left main
OR  odds ratio
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trialccepted November 29, 2012.
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346site-reported but not adjudicated by a CEC. Atrial
fibrillation (AF) and atrial flutter (AFL) were reported by
the investigative sites as serious adverse events and were
not adjudicated by the CEC. Stroke was assumed to be
directly correlated with AF/AFL whenever the timing of
events was interlinked and/or when this association was
confirmed in the patient chart narratives.
Statistical methods. Analysis was based on the intention-
to-treat principle and was conducted using SAS System
software (version 8.0 or higher, SAS Institute, Cary, North
Carolina). Data are summarized using descriptive statistics,
presented as percentage, count of sample size, or mean 
SD. The Student t test was used to compare continuous
ariables; differences in discrete variables were assessed by
eans of the chi-square or Fisher exact test, as appropriate.
The cumulative incidence of stroke was analyzed using
he Kaplan-Meier method. The binary rate of stroke was
nalyzed in pre-specified subgroups by lesion subsets (3VD
nd LM), sex, age (70 and 70 years), and the presence of
iabetes. Post hoc analyses according to prior stroke and/or TIA,
eripheral vascular disease, carotid artery disease, and SYN-
AX score tertiles were furthermore performed (low: 22,
ntermediate: 23 to 32, high: 33) (5). In-hospital outcome
omparisons between treatments and stroke rates within
hese subgroups do not seem appropriate because of the low
troke rate at this 30-day time point. Landmark analyses
fter 1-year follow-up were performed.
Univariate analysis, including a combination of pre-
perative and intraoperative variables believed to be clini-
Figure 1. Unadjusted Cumulative Stroke Rate to 4 Years Post-Allocation
Kaplan-Meier estimates (1.5  SE) for stroke in randomized patients treated
intervention (PCI) (yellow line) (A), CABG registry patients (green line) (B) or
error.ally relevant (Appendix), was used to identify potential
redictors of 4-year stroke. Subsequently, multivariate pre-
ictors were identified using stepwise selection with a
ignificance level of 0.10 for entry and exit in a logistic
egression model in the overall and the CABG, and PCI
ohorts separately; medically treated diabetes and LM/3VD
ere forced into the model based on previous findings.
redictors are expressed as odds ratio (OR)  95% confi-
ence interval (CI).
esults
Randomized arms. INCIDENCE OF STROKE. The 30-day
troke rate was 1% (9 of 897) after CABG and 0.2% (2 of
03) after PCI (p  0.037). At 4 years of follow-up, 3.7%
f CABG-randomized patients experienced stroke (n  31
atients, n  33 strokes) compared with 2.3% of PCI-
randomized patients (n  19 patients, n  20 strokes; p 
0.062) (Fig. 1). The majority of strokes were ischemic
(CABG: 29 of 33; PCI: 13 of 20).
Three patients in the CABG arm of the RCT suffered a
stroke before the index procedure (Fig. 2); 47 days before
treatment in 1 patient and on the day of randomization (3
days before surgery) in a second patient. One patient had a
stroke the day before the index procedure, 7 days after
allocation; this patient ultimately received medical therapy
and not CABG but was counted in the CABG group by
intention-to-treat. No pre-procedural strokes occurred in
the PCI arm. In those patients who experienced stroke, the
oronary artery bypass grafting (CABG) (blue line) or percutaneous coronary
gistry (red line) patients (C). p value in A from log-rank test. SE  standardwith c
PCI re
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347length of time between randomization and index procedure
was similar between treatment arms (CABG: 12.6  22.4
ays [median: 6 (interquartile range [IQR]: 2 to 11 days)]
s. PCI 17.5  38.8 days [median: 2 (IQR: 1 to 6 days)]).
BASELINE AND PROCEDURAL CHARACTERISTICS. Baseline
characteristics of the randomized cohort of SYNTAX are
Figure 2. Timing of Stroke Relative to Treatment Group Allocation and Ind
The date of allocation (), index procedure (), ﬁrst stroke ( ), and second st
dotted gray lines indicate yearly follow-up intervals and the (*) indicates tho
Figure 1.
Table 1. Baseline Characteristics of RCT Stroke Pati
All Patients
(N  1,800)
Stro
Patie
(n 
Age, yrs 65.1 9.7 (1,800) 67.7 9
Female 22.3 (402/1,800) 29.0 (9
Prior stroke 4.4 (78/1,789) 0 (0
Prior TIA 4.7 (84/1,789) 10.0 (3
Carotid artery disease 8.2 (148/1,800) 16.1 (5
Peripheral artery disease 9.8 (177/1,800) 22.6 (7
History of smoking 64.7 (1,160/1,793) 74.2 (2
Current smoker 20.2 (363/1,793) 29.0 (9
Medically treated diabetes 25.1 (452/1,800) 29.0 (9
Hypertension 75.5 (1,349/1,787) 93.5 (2
Logistic EuroSCORE 3.8 4.5 (1,800) 4.6 3
Mean SYNTAX score 28.7 11.4 (1,789) 29.1 1
Values are mean SD (N) or % (n/N).
CABG  coronary artery bypass grafting; EuroSCORE  European
intervention; RCT randomized controlled trial; SYNTAX Synergy BTIA transient ischemic attack.presented in Table 1. Patients who experienced stroke were
older and had more severe cardiovascular disease as defined
by increased incidences of prior cerebrovascular events,
peripheral vascular disease, hypertension, and a higher mean
logistic EuroSCORE (European System for Cardiac Oper-
ative Risk Evaluation).
cedure in the Randomized Controlled Trial
f applicable (‘), in each patient are represented on a single line. The
kes that occurred before the index procedure. Abbreviations as in
CABG PCI
Nonstroke
Patients
(n  866)
Stroke
Patients
(n  19)
Nonstroke
Patients
(n  884)
64.9 9.8 (866) 71.5 8.0 (19) 65.1 9.7 (884)
20.8 (180/866) 26.3 (5/19) 23.5 (208/884)
5.0 (43/860) 10.5 (2/19) 3.8 (33/880)
4.9 (42/858) 10.5 (2/19) 4.2 (37/882)
8.1 (70/866) 0 (0/19) 8.3 (73/884)
10.2 (88/866) 15.8 (3/19) 8.9 (79/884)
68.9 (592/859) 63.2 (12/19) 60.3 (533/884)
21.8 (187/859) 15.8 (3/19) 18.6 (164/884)
24.5 (212/866) 26.3 (5/19) 25.6 (226/884)
76.4 (657/860) 89.5 (17/19) 73.7 (646/877)
3.9 4.4 (866) 6.1 5.9 (19) 3.7 4.5 (884)
) 29.1 11.4 (859) 31.8 10.4 (19) 28.3 11.5 (880)
for Cardiac Operative Risk Evaluation; PCI  percutaneous coronary
Percutaneous Coronary InterventionWith Taxus and Cardiac Surgery;ex Pro
roke, i
se stroents
ke
nts
31)
.2 (31)
/31)
/30)
/30)
/31)
/31)
3/31)
/31)
/31)
9/31)
.3 (31)
1.2 (31
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348The rate of off-pump bypass surgery was 15% (128 of
853) in the randomized CABG patient population, with
a similar cumulative 4-year stroke rate of 3.6% in the
off-pump group compared with 3.5% in patients that
underwent on-pump surgery (p  0.98 by log rank).
AF and/or AFL during follow-up were reported in 3.4%
31 of 903) after PCI and in 7.9% (71 of 897) after CABG.
he rate of stroke in patients with versus without arrhyth-
ia was 9.7% (3 of 31) versus 1.8% (16 of 872) after PCI
nd 5.6% (4 of 71) versus 3.3% (27 of 826) after CABG.
In general, patients in the PCI cohort received dual anti-
latelet therapy at greater rates before, during, and after the
ndex procedure compared with CABG patients up to 3 years
ollowing randomization (4-year data not available) (12).
OUTCOMES AFTER STROKE. Of the RCT patients who had
strokes, 3 in each treatment arm died because of the event (PCI
vs. CABG, p  0.66) (Fig. 3). The median length of stay in
the hospital—whether this was the index hospitalization or
readmission—in patients experiencing stroke was 8 days in the
CABG arm (IQR: 7 to 14 days) and 7 days (IQR: 2 to 21 days)
in the PCI arm. Overall, after the stroke, patients were
discharged equally to home or to a rehabilitation facility.
There were 7 patients (23%) in the CABG group and 7
patients (37%) in the PCI group that were alive with no
Figure 3. Outcomes After StrokeNearly all patients who experienced a stroke were discharged either to home or to along-term residual deficits after stroke (p  0.28) (Fig. 3).
The remaining 21 (68%) and 9 (47%) surviving CABG and
PCI patients, respectively, had residual deficits that in-
cluded though not limited to: hypoesthesia/numbness; mo-
tor deficits; language deficits; visual deficits; muscle weak-
ness; muscle spasms; paresis/paralysis; and dysphasia. The
most common residual symptoms were language deficit and
paresis/paralysis.
SUBGROUPS. In the subgroup of RCT patients with LM
disease, stroke was significantly increased in CABG-treated
patients (CABG: 4.3% [n  14] vs. PCI: 1.5% [n  5]; p 
0.03); whereas, in patients with 3VD, no significant difference
was found (3.4% [n  17] vs. 2.8% [n  14]; p  0.53). No
significant differences in stroke were found between
pre-specified subgroups of sex, age, or the presence of
diabetes, nor in post-hoc analyses according to prior
stroke and/or TIA, or the presence of carotid artery
disease (Fig. 4).
Although no statistical comparisons were made because
of the low number of events, it was noted that the stroke
rate in the CABG and PCI arms of the RCT was differ-
entially affected by complexity of coronary artery disease as
measured by the SYNTAX score. In CABG-randomized
patients, the stroke rate was similar in each SYNTAX scorerehabilitation center. Abbreviations as in Figures 1 and 2.
t2
w
5
B
a
p
c
h
w
s
s
o
l
t
h
f
f
p
t
T
d
r
m
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 4 , 2 0 1 3 Mack et al.
A P R I L 2 0 1 3 : 3 4 4 – 5 4 Analysis of Stroke After CABG or PCI
349tertile (low SYNTAX score: 4% [n  10], intermediate:
3.6% [n  10], and high: 3.7% [n  11]). A stepwise
increase in the risk of stroke was found within SYNTAX
score tertiles in PCI-treated patients (low: 1.4% [n  4],
intermediate: 2% [n  6], and high: 3.5% [n  9]).
PREDICTORS OF STROKE. By multivariate analysis, the pre-
dictors with the greatest impact on likelihood of stroke
within 4 years in all randomized patients were age per 10
years, hypertension, moderate or poor left ventricular ejec-
tion fraction, and Canadian Cardiovascular Society angina
class 3/4 (Table 2). Treatment with CABG was not
significantly associated with increased stroke rates (OR:
1.67, 95% CI: 0.93 to 3.01; p  0.089).
In the PCI arm, several markers of the severity of
cardiovascular disease (e.g., previous myocardial infarction,
peripheral vascular disease, moderate or poor left ventricular
ejection fraction, and Canadian Cardiovascular Society an-
gina class 3/4) were found to be predictors of stroke within
4 years. In the CABG arm, patients had an increased risk of
stroke if they were older and had previously experienced a
TIA or stroke.
Nested registries. The CABG registry (n  644 followed
for 5 years) predominantly included patients in whom PCI
was not considered technically feasible by the heart team,
and the PCI registry (n  198) included patients in whom
it was felt that the outcome of CABG would be unfavorable
(10). As a result, patients in the CABG registry are
comparable to the randomized trial except on SYNTAX
score (37.8  13.3 vs. 29.1  11.4 in the trial). In contrast,
Figure 4. Rate of Stroke at 4 Years in Pre-Defined and Post Hoc Subgroup
The percentage of patients experiencing a stroke within 4 years of follow-up (
with left main (LM) or 3-vessel disease (3VD) (without LM disease), patients wi
older than 70 years of age, patients with or without carotid artery disease (CA
Abbreviations as Figure 1.patients in the PCI registry had similar lesion complexity wbut higher logistic EuroSCORE (7.7  9.0 vs. 3.8  4.5 in
he trial).
The rate of stroke in the CABG registry was 4.2% (n 
6 patients, n  29 strokes) at 4 years of follow-up; there
ere 3 patients that had 2 strokes. The rate was 3.1% (n 
patients, n 5 strokes) in the PCI registry (Figs. 1B and 1C).
aseline characteristics of the PCI and CABG registries
re presented in Table 3. Similar to randomized cohorts,
atients who experienced stroke more often had prior
erebrovascular events, peripheral vascular disease, or
ypertension.
Off-pump CABG was performed in 120 patients, of
hich 6 patients had a stroke. Twenty patients suffered a
troke after on-pump CABG. The cumulative rate of
troke was 5.3% and 4% in patients that underwent
ff-pump and on-pump surgery, respectively (p  0.57 by
og rank).
In the CABG registry, 3 patients suffered strokes that led
o death. There were 26 discharges of which 14 were to
ome, 8 were to a rehabilitation center, and 4 to another
acility. Seven (27%) CABG registry patients recovered
rom the stroke without residual deficits. The median
ost-stroke hospital stay was 11 days (range 6 to 21 days). In
he PCI registry, 1 patient died as the result of a stroke.
hree patients were discharged with residual deficits; 1 was
ischarged home and 2 to another facility. One patient
ecovered from the stroke without residual deficits. The
edian hospital stay after the stroke in PCI registry patients
 blue; PCI  orange/yellow) in the overall patient population, patients
ithout medically treated diabetes, men and women, patients younger or
d patients with or without prior transient ischemic attack (TIA) and/or stroke.s
CABG
th or w
D), anas 12 days (range 7 to 14 days).
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350Discussion
The overall incidence of stroke was low at 4 years in the
SYNTAX trial and was not significantly different between
PCI and CABG. In the short term after treatment, patients
that underwent CABG were more likely to experience a
Table 2. Univariate and Multivariate Predictors of St
Univariate OR
(95% CI)
Overall cohort (N  1,800)
Age per 10 yrs 1.65 (1.21–2.25)
Hypertension 4.02 (1.44–11.24)
Peripheral vascular disease 2.37 (1.16–4.84)
Moderate or poor LVEF 2.02 (1.10–3.71)
Angina class CSS 3/4 1.79 (0.99–3.22)
CABG treatment group 1.78 (1.00–3.18)
Medically treated diabetes* —
Left main disease* —
PCI cohort (n  903)
Previous MI 0.29 (0.10–0.84)
Hypertension 4.67 (1.10–19.76)
Peripheral vascular disease 2.58 (1.08–6.18)
Moderate or poor LVEF 1.99 (0.92–4.32)
Angina class CSS 3/4 2.27 (1.09–4.73)
Medically treated diabetes* —
Left main disease* —
CABG cohort (n  897)
Age per 10 yrs 2.41 (1.38–4.20)
Prior TIA or stroke 3.43 (1.11–10.66)
Medically treated diabetes* —
Left main disease* —
*Forced into the model.
CI confidence interval; CSS Canadian Cardiovascular Society; LV
ratio; other abbreviations as in Table 1.
Table 3. Baseline Characteristics of Registry Stroke Patients
CABG Registry
Overall
(N  644)
Stroke Patients
(n  26)
Non
Age, yrs 65.7 9.4 (644) 67.0 9.7 (26) 65
Female 19 (124/644) 35 (9/26) 1
Prior stroke 6 (35/639) 12 (3/25)
Prior TIA 6 (36/638) 19 (5/26)
Carotid artery disease 12 (79/644) 19 (5/26) 1
Peripheral artery disease 14 (89/644) 19 (5/26) 1
History of smoking 64 (411/639) 65 (17/26) 6
Current smoker 22 (140/639) 19 (5/26) 2
Medically treated diabetes 26 (170/644) 35 (9/26) 2
Hypertension 74 (465/633) 88 (23/26) 7
Logistic EuroSCORE 4.0 4.4 (644) 5.2 5.2 (26) 4
SYNTAX score 37.8 13.3 (632) 35.8 12.8 (25) 37
Values are mean SD (N) or % (n/N).Abbreviations as in Tables 1 and 2.stroke than were PCI-treated patients. After this procedure-
related risk, a similar stroke hazard was found in PCI and
CABG patients during follow-up.
Whereas large registries and randomized trials comparing
PCI and CABG have mainly focused on survival, myocar-
dial infarction, and repeat revascularization, stroke is par-
p Value
Multivariate OR
(95% CI) p Value
0.001 1.56 (1.14–2.14) 0.006
0.008 3.47 (1.23–9.80) 0.019
0.017 1.96 (0.94–4.10) 0.071
0.023 2.06 (1.08–3.95) 0.029
0.052 1.84 (1.01–3.35) 0.048
0.051 1.67 (0.93–3.01) 0.089
— 0.91 (0.47–1.77) 0.790
— 0.83 (0.46–1.53) 0.559
0.023 0.18 (0.05–0.62) 0.007
0.036 4.10 (0.95–17.62) 0.058
0.033 2.73 (1.09–6.83) 0.031
0.081 2.62 (1.12–6.14) 0.027
0.028 2.54 (1.18–5.46) 0.017
— 0.88 (0.37–2.06) 0.762
— 1.04 (0.49–2.23) 0.915
0.002 2.57 (1.43–4.63) 0.002
0.033 3.58 (1.13–11.38) 0.031
— 1.03 (0.36–2.94) 0.956
— 0.49 (0.17–1.40) 0.186
ft ventricular ejection fraction; MImyocardial infarction; OR odds
PCI Registry
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351ticularly underrepresented from such studies (13–15). Es-
pecially assessments of stroke over long-term follow-up
have been limited. Yet, in-depth analysis of stroke is crucial
to determine the true risk/benefit ratio of PCI and CABG,
weighing the risk of stroke versus the risk of repeat
revascularization (16). In our report, the hazard of stroke
during follow-up was low and there was a similar incidence
of stroke after PCI and CABG, providing reassuring infor-
mation especially for the surgical perspective. Nevertheless,
the outcome of patients in this cohort was poor; stroke led
to death in 6 patients (CABG: n  3, PCI: n  3) and a
significant amount of surviving patients experienced long-
term residual impairment after the stroke (CABG: 68%,
PCI: 47%).
Procedure-related stroke remains a serious complication
after isolated CABG occurring in as many as 1% to 4% of
patients (5,8,17,18). Previous nonrandomized studies of
CABG versus PCI in LM or multivessel-disease patient
populations have found either an increase in stroke in
CABG-treated patients (6,7) or no difference in stroke rate
(19–21). However, data from randomized trials are limited
and, like SYNTAX’s data, are not powered to detect a
significant difference in stroke rate. A meta-analysis of 7
randomized trials comparing PCI (with balloon angioplasty
of bare-metal stents) with CABG for multivessel disease
showed that the 90-day stroke rate after randomization to
PCI was significantly lower (0.5% vs. 1.1%, p  0.02) (8).
Moreover, Daemen et al. (22) reported in a meta-analysis of
5 randomized trials using bare-metal stents that rates appear
to be comparable at 5-year follow-up: 3.6% versus 3.1% for
CABG and PCI, respectively. After adjustment for several
clinical characteristics, there was little evidence of a benefit
for either treatment, with an adjusted hazard ratio of 1.16
(95% CI: 0.73 to 1.83). Considering these data, the results
presented here of the SYNTAX trial are comparable to
other trials comparing PCI with CABG. However, the
recent results from the FREEDOM (Future Revasculariza-
tion Evaluation in Patients With Diabetes Mellitus: Opti-
mal Management of Multivessel Disease) trial showed a
significant increase in stroke at 5-year follow-up after
CABG as compared with PCI in 1,900 randomized diabetic
patients (23).
Attempts to improve outcomes after surgical coronary
revascularization should be directed toward reducing the
rate of stroke. Indeed, some studies have shown a stroke
benefit with off-pump surgery due to avoidance of cardio-
pulmonary bypass and indirectly by reducing the rate of
AF/AFL (24). In SYNTAX, 15% of randomized and 18.6%
of registry CABG patients underwent off-pump surgery. No
differences in rates of stroke in the trial (3.6% vs. 3.5% with
on-pump) nor in the registry (5.3% vs. 4.0% with on-pump)
were found, suggesting no benefit of off-pump CABG in
reducing the rate of stroke. However, no data were available
on manipulation of the ascending aorta or the use ofepiaortic scanning, so whether off-pump surgery would truly
be beneficial cannot be evaluated. Furthermore, the num-
bers treated with the off-pump technique were small, and no
firm conclusions should be based on these data. It should
not be expected that off-pump surgery is useful in all
patients undergoing isolated CABG, but it could be more
beneficial to consider it merely for subgroups of patients
with, for example, severe aortic calcification (25,26). Further
efforts should be directed in screening the aorta and in the
use of “no touch” off-pump CABG.
New-onset AF occurs in up to 40% of patients shortly
after cardiac surgery and has clearly been associated with an
increase in the incidence of stroke (27). Very limited data
are available on AF during follow-up after revascularization.
One study reported AF during follow-up in 11.4% of
patients after CABG, but it did not find that this was
related to stroke (28). In the SYNTAX trial, we found a low
rate of AF/AFL during follow-up (PCI: 3.4%, CABG:
7.9%). The low incidence of AF and the smaller fraction of
AF patients who experienced stroke make it difficult to draw
any meaningful conclusions regarding the relationship be-
tween AF/AFL and stroke, especially when considering that
the arrhythmia event was not adjudicated by the CEC. In
this regard, the correlation between AF/AFL and stroke
was only based on chart narratives, whereas the rate of
stroke was clearly higher in patients with late arrhythmia.
Unfortunately, AF could not be added to the univariate and
multivariate analyses because it was considered an adverse
event by itself, occurring late during follow-up.
Despite technical improvements, the cause of stroke after
revascularization is multifactorial and depends on many
more factors, which are also relevant for patients treated
with PCI. The presence of multivessel disease has been
shown to independently predict stroke after both PCI and
CABG (29,30). In SYNTAX, the incidence of stroke in the
PCI arm, but not the CABG arm, increased with SYNTAX
score tertile, suggesting that stroke occurs more frequently
in complex disease. Looking more specifically to LM or
3VD subgroups, LM disease has been shown to be a
correlate of carotid artery disease, which may increase stroke
in LM CABG patients (30–32). Additionally, aortic ma-
nipulation may be more prevalent in the LM subgroup than
in the 3VD subgroup, suggesting that the likelihood of
stroke is higher in the LM subgroup. Nevertheless, LM and
3VD were not significantly associated with stroke in the
overall, PCI, or CABG multivariate models.
There is significant variation in the incidence of stroke among
different subgroups of patients. Diabetes, female sex, prior TIA or
stroke, and advanced age may influence the risk of stroke poten-
tially because of widespread cerebrovascular disease, impaired
cerebral blood flow, and/or increased susceptibility to atheroem-
bolism or thromboembolism (29,30,33–37). Examining these
subgroups in the SYNTAX patient population, there is a
nonsignificant difference in the timing of stroke events in
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352these subgroups that could affect potential preventive or
treatment strategies. The timing of strokes in the PCI arm
of these subgroups occurs throughout follow-up, whereas in
CABG-treated patients, most strokes occur in the first year.
In the multivariate analysis, we found that advanced age
emerged as a significant independent predictor of stroke in
the overall patient population as well as in the CABG-
treated cohort. Furthermore, several factors (e.g., hyperten-
sion or moderate or poor left ventricular ejection fraction)
that have been shown to predict stroke (38) indeed emerged
as independent predictors in our analysis. Patients in the
randomized trial and nested registries that suffered a stroke
more often had prior cerebrovascular events. Clearly, this
factor is related to an increased risk of stroke after revascu-
larization, although we were only able to confirm this
through multivariate analyses in the CABG cohort.
Furthermore, female sex and diabetes did not emerge as
significant predictors of stroke, but these results may be
the consequence of the low number of events.
The length of time between randomization and treatment
was similar in those CABG and PCI patients who suffered
a stroke, suggesting the numeric increase in pre-procedural
stroke in the CABG arm was not related to a delay in
surgical therapy. Nevertheless, patients randomized to
CABG would have been less likely to receive antiplatelet
therapy while awaiting their index revascularization. This
may have influenced the pre-procedure stroke rate as dual
antiplatelet therapy has been shown to reduce the risk of a
major vascular event compared with aspirin alone (though it
is less effective than oral anticoagulant therapy) (39,40).
There were 3 pre-procedure strokes in the CABG arm; 1
stroke may have been the result of pre-operatively discon-
tinuing antiplatelet medications, because the stroke oc-
curred on the day before the procedure when the platelet
count would have been relatively high. The other 2 strokes
were unlikely to be related to discontinued medications due
to the timing of the stroke.
As dual antiplatelet therapy is not the accepted standard
of care for post-CABG patients, the overall increase in
stroke could have been influenced by the reduced use of
aspirin or other antiplatelet agents in the CABG arm.
However, the cause of stroke in PCI and CABG cohorts
could be different, and even if medication use was compa-
rable, this may only have a limited affect on stroke rates.
Still, establishing clinical directives for aggressive medical
therapy in CABG patients might result in a decrease in
stroke risk and is worthy of further study.
Study limitations. Although this analysis provides contem-
orary insights into the incidence of stroke in a complex
CI- and CABG-treated patient population, it is under-
owered to detect a difference in stroke rate. Furthermore,
ore patients withdrew consent (or were lost to follow-up)
n the CABG treatment arm, which may have affected our
ndings, although this is unlikely (12).Data on pre-operative AF or new AF during index
evascularization admission was not recorded in the
YNTAX trial and, therefore, such analyses could not be
ncluded. Follow-up data on AF or AFL were reported by
nvestigation sites as adverse events and were not adju-
icated by an independent CEC; therefore, the conclu-
ions derived from these data are limited. Furthermore,
atient-level details concerning the level of aortic manipulation
nd the presence of asymptomatic carotid stenosis and mild
europsychological disturbance pre- and post-revascularization
ere not captured.
Finally, a rule of thumb regarding multivariate analyses is
o include 1 covariate per 10 events. We have limited the
nclusion of covariates strictly to those deemed clinically
elevant, but still we have overfitted the model to include
ore covariates. Therefore, these data from the multivariate
nalyses should be interpreted with caution. However, the
imited number of stroke comparisons from randomized
CI versus CABG trials was an incentive to overfit the
odel, as this may provide novel hypothesis-generating data
s to the multifactorial cause of stroke after myocardial
evascularization.
onclusions
The overall incidence of stroke was low at 4 years in the
SYNTAX trial in both CABG- and PCI-treated patients.
Though more strokes occurred in the CABG arm than in
the PCI arm early in the study, no significant differences
were found at 4 years and the outcome of stroke after PCI
and CABG was similar.
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354Appendix
Variables included in univariate and
multivariate logistic regression analyses
In the overall model: age per 10 years increase, sex,
previous MI, prior transient ischemic attack (TIA) or
stroke, medically treated diabetes, angina class, cigarette
use, hypertension, hyperlipidemia, carotid artery disease, (3VD/left main (LM), moderate or poor LVEF, renal
failure (creatinine 200 mol/L), peripheral vascular
isease, overall SYNTAX score, number of vessels
reated, treatment group.
In addition for the percutaneous coronary intervention
PCI) model: antiplatelet medication compliance.
In addition for the coronary artery bypass grafting
CABG) model: off-pump.
